Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;60(5):277–300.
   Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–8261. doi:10.1200/JCO.2005.03.477716278481
   PubMed Web of Science ®Google Scholar
• Lin DW. Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Urol Oncol Semin Ori. 2009;27(6):690–691.
   Google Scholar
• Yu C, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2010;57(2):356–357.
   Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med. 1998;339(15):1036–1042. doi:10.1056/NEJM1998100833915049761805
   PubMed Web of Science ®Google Scholar
• Aneja S, Pratiwadi RR, Yu JB. Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system. Oncology. 2012;26(6):512.22870533
   PubMed Web of Science ®Google Scholar
• Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27–34. doi:10.1016/S0022-5347(05)00034-016406864
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003;62(6B):87–94. doi:10.1016/j.urology.2003.10.00214747046
   PubMed Web of Science ®Google Scholar
• Kosaka T, Miyajima A, Nagata H, Maeda T, Kikuchi E, Oya M. Human castration resistant prostate cancer rather prefer to decreased 5alpha-reductase activity. Sci Rep. 2013;3:1268.23429215
   PubMed Web of Science ®Google Scholar
• Ezzi AAE, Baker MT, Zaidan WR, Hraiki KM, Saidi MAE, Kuddus RH. Association of polymorphisms in the VDR, CYP17 and SRD5A2 genes and prostate cancer among lebanese men. Asian Pac J Cancer Prev. 2017;18(1):93–100. doi:10.22034/APJCP.2017.18.1.9328240015
   PubMedGoogle Scholar
• Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005;1(5):e68.16311626
   PubMed Web of Science ®Google Scholar
• Han JH, Lee YS, Kim HJ, Lee SY, Myung SC. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population. Asian J Androl. 2015;17(2):285–291. doi:10.4103/1008-682X.13332025337833
   PubMed Web of Science ®Google Scholar
• Risio M, Venesio T, Kolomoets E, et al. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol. 2011;35(4):e18–e24. doi:10.1016/j.canep.2010.10.00321094112
   PubMedGoogle Scholar
• Salvi S, Casadio V, Burgio SL, et al. CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. Int J Biol Markers. 2016;31(3):e264–e269. doi:10.5301/jbm.500019726954071
   PubMed Web of Science ®Google Scholar
• Kanda S, Tsuchiya N, Narita S, et al. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival. Int J Cancer. 2015;136(1):74–82. doi:10.1002/ijc.2895224803183
   PubMed Web of Science ®Google Scholar
• Zhenfei L, Bishop AC, Mohammad A, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523(7560):347–351. doi:10.1038/nature1440626030522
   PubMed Web of Science ®Google Scholar
• Akhtar MK, Kelly SL, Kaderbhai MA. Cytochrome b5 modulation of 17α hydroxylase and 17–20 lyase (CYP17) activities in steroidogenesis. J Endocrinol. 2005;187(2):267–274. doi:10.1677/joe.1.0637516293774
   PubMed Web of Science ®Google Scholar
• Davis SM, Squires EJ. Association of cytochrome b5 with 16-androstene steroid synthesis in the testis and accumulation in the fat of male pigs. J Anim Sci. 1999;77(5):1230–1235. doi:10.2527/1999.7751230x10340591
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69(12):4937–4940. doi:10.1158/0008-5472.CAN-08-453119509232
   PubMed Web of Science ®Google Scholar
• Wang F, Zou YF, Feng XL, Su H, Huang F. CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate. 2011;71(11):1167–1177. doi:10.1002/pros.2133221656827
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913–5925. doi:10.1158/1078-0432.CCR-11-072821807635
   PubMed Web of Science ®Google Scholar
• Binder M, Zhang BY, Hillman DW, et al. Common genetic variation in CYP17A1 and response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Int J Mol Sci. 2016;17(7):1097.
   Web of Science ®Google Scholar
• Wright JL, Kwon EM, Lin DW, et al. CYP17 polymorphisms and prostate cancer outcomes. Prostate. 2010;70(10):1094–1101. doi:10.1002/pros.2114320503394
   PubMed Web of Science ®Google Scholar
• Stark K, Schmidt M, Rovenský J, Blažičková S, Lowin T, Straub RH. Influence of CYB5A gene variants on risk of rheumatoid arthritis and local endocrine function in the joint. Brain Behav Immun. 2013;29:S12–S13.
   Google Scholar
• Stark K, Straub RH, Rovenský J, Blažičková S, Eiselt G, Schmidt M. CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women. Arthritis Res Ther. 2015;17(1):1–11. doi:10.1186/s13075-014-0514-025566937
   PubMed Web of Science ®Google Scholar
• Livak KJ. Allelic discrimination using fluorogenic probes and the 5ʹ nuclease assay. Genet Anal. 1999;14(5–6):143–149. doi:10.1016/s1050-3862(98)00019-910084106
   PubMedGoogle Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26(7):1148–1159. doi:10.1200/JCO.2007.12.448718309951
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151. doi:10.1210/er.2010-001321051590
   PubMed Web of Science ®Google Scholar
• Billen MJ, Squires EJ. The role of porcine cytochrome b5A and cytochrome b5B in the regulation of cytochrome P45017A1 activities. J Steroid Biochem Mol Biol. 2009;113(1–2):98–104. doi:10.1016/j.jsbmb.2008.11.01219101629
   PubMed Web of Science ®Google Scholar
• Idkowiak J, Randell T, Dhir V, et al. A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency. J Clin Endocrinol Metab. 2012;97(3):E465–E475. doi:10.1210/jc.2011-241322170710
   PubMed Web of Science ®Google Scholar
• Severi G, Hayes VM, Tesoriero AA, et al. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int. 2008;101(4):492–496. doi:10.1111/j.1464-410X.2007.07272.x17986287
   PubMed Web of Science ®Google Scholar
• Han QH, Shan ZJ, Hu JT, Zhang N, Zhang XP. Relationship between gene polymorphisms and prostate cancer risk. Asian Pac J Trop Med. 2015;8(7):569–573. doi:10.1016/j.apjtm.2015.06.00526276290
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer from the national cancer institute breast and prostate cancer cohort consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007;16(11):2237–2246. doi:10.1158/1055-9965.EPI-07-058918006912
   PubMed Web of Science ®Google Scholar
• Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the flint men’s health study. Prostate. 2008;68(3):296–305. doi:10.1002/pros.2069618163429
   PubMed Web of Science ®Google Scholar
• Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12(2):120–126.12582021
   PubMed Web of Science ®Google Scholar
• Taioli E, Sears V, Watson A, et al. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate. 2013;73(6):668–676. doi:10.1002/pros.2261223129512
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakayama M, Shimizu T, et al. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy. Int J Clin Oncol. 2013;18(4):711–717. doi:10.1007/s10147-012-0430-822714708
   PubMed Web of Science ®Google Scholar
• Yoshimoto FK, Auchus RJ. The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1). J Steroid Biochem Mol Biol. 2015;151:52–65. doi:10.1016/j.jsbmb.2014.11.02625482340
   PubMed Web of Science ®Google Scholar
• Squires EJ, Gray MA, Lou Y. Effect of mutations in porcine CYB5A and CYP17A1 on the metabolism of pregnenolone. J Steroid Biochem Mol Biol. 2019;195:105469.31509771
   PubMed Web of Science ®Google Scholar
• Barnard M, Mostaghel EA, Auchus RJ, Storbeck KH. The role of adrenal derived androgens in castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2020;197:105506.31672619
   PubMed Web of Science ®Google Scholar
• Peacock J, Lou Y, Lundström K, Squires EJ. The effect of a c.-8G>T polymorphism on the expression of cytochrome b5A and boar taint in pigs. Anim Genet. 2008;39(1):15–21. doi:10.1111/j.1365-2052.2007.01674.x18162105
   PubMed Web of Science ®Google Scholar